Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (4): 640-646. doi: 10.19723/j.issn.1671-167X.2021.04.003

Previous Articles     Next Articles

Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma

YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun(),LI Xue-song()   

  1. National Urological Cancer Center, Beijing 100034, China
  • Received:2021-01-11 Online:2021-08-18 Published:2021-08-25
  • Contact: Qun HE,Xue-song LI E-mail:bdyyqhe@sina.com;pineneedle@sina.com
  • Supported by:
    Scientific Research Seed Fund of Peking University First Hospital(2020SF36)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma (FH-RCC). Methods: Immunohistochemical (IHC) staining was used to detect the expression of fumarate hydratase (FH) in tumor tissues of 109 different types of renal cell carcinoma (RCC) patients aged 60 years and younger from the Department of Urology of Peking University First Hospital from January 2013 to December 2019. The clinicopathological data and prognosis of FH-RCC were collected and analyzed. Results: There were eleven patients with FH-negative expression. Seven were males and four females. The age of onset ranged 16-53 years (mean age: 36.7 years), and four female patients all had a history of uterine leiomyoma. Only one first-degree relative of one patient had renal cancer, and none of the patients had a history or family history of cutaneous leiomyomas. The diameter of the tumor was 2.1-12.0 cm (mean: 8.83 cm). Renal sinus or perirenal fat invasion was seen in nine cases, tumor thrombus in renal vein or inferior vena cava in six cases, lymph node metastasis in seven cases, adrenal gland invasion in four cases and splenic capsule invasion in one case. The cases were initially diagnosed as type Ⅱ papillary RCC (7/49, 14.3%), collecting duct carcinoma (2/9, 22.2%) and unclassified RCC (2/51, 3.9%). Tumor histopathology mostly showed a mixture of different structures, such as papillary, tubular cystic, solid, and so on. The most common histological structures were papillary (9/11, 81.8%) and tubular (8/11, 72.7%). Three cases had sarcomatoid areas. At least focal eosinophilic nucleolus (WHO/grades Ⅲ-Ⅳ) and perinuclear halo could be seen in all cases. Immunohistochemical (IHC) stains of most tumors were negative for CA9, CD10 and CK7. The results of fluorescence in situ hybridization (FISH) showed that there was no translocation or amplification of TFE3 gene in two cases with TFE3 IHC expression. All the patients were followed up for 11-82 months. Mean survival was 24 months. Five cases died of distant metastasis 9-31 months after operation (mean: 19 months), and five of the six patients alive had became metastatic. Conclusion: Morphologically, FH-RCC overlaps with many types cell RCC. A mixture of papillary and tubular cystic arrangement is the most common growth pattern of FH-RCC. At least focally large and obvious eosinophilic nucleoli are an important histological feature of this tumor. The negative expression of FH can help to confirm the diagnosis. Young female RCC patients with uterine leiomyomas should be suspected of FH-RCC. Some FH-RCC cases lack clinical evidence. The suspicion raised by pathologists based on histological characteristics is often the key step to further genetic testing and the final diagnosis of the tumor.

Key words: Renal cell carcinoma, Fumarate hydratase, Immunohistochemistry, Prognosis

CLC Number: 

  • R737.11

Table 1

Clinical features of FH-RCC"

Patient
No.		 Gender Age/
years		 Presentation Personal history Family history Tumor
location		 Distant metastasis OS/month
1 M 39 Flank pain - Uterine leiomyomas Right Liver, thoracic
vertebrae		 11.3
2 F 35 Physical examination Uterine leiomyomas,
adrenal cortical hyperplasia		 Uterine leiomyomas Left Omentum 12.5
3 F 26 Flank pain Uterine leiomyomas RCC Right Bone 13.2
4 M 34 Physical examination - - Left Bone, diaphragm 20.0
5 M 16 Flank pain - Uterine leiomyomas Left - 9.2 (DOD)
6 M 53 Physical examination - - Right Bone 16.6 (DOD)
7 M 37 Physical examination - Uterine leiomyomas Left Rectum 32.8
8 F 40 Physical examination Multiple uterine leiomyomas Uterine leiomyomas Left - 17.2 (DOD)
9 M 48 Hematuria - - Left Unkown 17.2 (DOD)
10 F 28 Flank pain Uterine leiomyomas Uterine leiomyomas,
colorectal carcinoma		 Right - 31.5 (DOD)
11 M 48 Hematuria Cystic nephroma - Right - 82.7

Table 2

Pathologic features of FH-RCC"

Patient No. Size/cm Initial histological type Fuhrman grade pTNM stage Histological structures
Solid Papillary Tubulocystic Cribriform
1 12.0 PRCC Ⅱ G3 pT3aN1 - Yes Yes Yes
2 6.5 PRCC Ⅱ G3 pT3aN1 - Yes Yes -
3 11.0 PRCC Ⅱ G3 pT2b - Yes Yes -
4 6.5 PRCC Ⅱ G3 pT4N1 Yes Yes - -
5 8.5 PRCC Ⅱ G3 pT4N1 - Yes - -
6 10.5 CDC G3 pT4N1 Yes Yes Yes -
7 12.0 U-RCC G4 pT4N1 Yes Yes Yes Yes
8 9.0 U-RCC G3 pT3aN1 - Yes Yes Yes
9 8.0 PRCC Ⅱ G3 pT3bN2 Yes Yes Yes -
10 11.0 PRCC Ⅱ G3 T3a - Yes Yes -
11 2.1 CDC G3 pT1a - - Yes -

Figure 1

The histological features of fumarate hydratase-deficient renal cell carcinoma (HE ×40) A, papillary structure, resembling type Ⅱ papillary renal cell carcinoma; B, tubular structure, resembling collecting duct carcinoma and high magnification shows eosinophilic (viral inclusion-like) macronucleoli with perinucleolar clearing (lower left, HE ×200); C, cystic structure; D, cribriform and tubular structure; E, solid structure; F, sarcomatoid area."

Figure 2

Immunohistochemical staining (×40) A, positive FH staining of non-FH-RCC (lower right) and normal kidney tissue (upper left); B, negative FH staining of FH-RCC and positive FH staining of residual normal renal tubules (arrow); C, diffuse strong positive staining of TFE3. FH, fumarate hydratase; FH-RCC, fumarate hydratase-deficient renal cell carcinoma."

[1] Pivovarcikova K, Martinek P, Grossmann P, et al. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases [J]. Ann Diagn Pathol, 2019, 39:63-68.
doi: S1092-9134(19)30031-0 pmid: 30785029
[2] 周婷婷, 邢金春. FH基因在遗传性平滑肌瘤病及肾癌综合征中的研究进展 [J]. 医学综述, 2014, 20(5):881-884.
[3] Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43 [J]. Am J Hum Genet, 2001, 68(5):1264-1269.
pmid: 11283798
[4] Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer [J]. Nat Genet, 2002, 30(4):406-410.
pmid: 11865300
[5] Hansen AW, Chayed Z, Pallesen K, et al. Hereditary leiomyomatosis and renal cell cancer [J]. Acta Derm Venereol, 2020, 100(1): adv00012.
[6] Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: Recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry [J]. Am J Surg Pathol, 2014, 38(5):627-637.
doi: 10.1097/PAS.0000000000000163
[7] Patel VM, Handler MZ, Schwartz RA, et al. Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review [J]. J Am Acad Dermatol, 2017, 77(1):149-158.
doi: 10.1016/j.jaad.2017.01.023
[8] Alam NA, Barclay E, Rowan AJ, et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: An underdiagnosed tumor syndrome [J]. Arch Dermatol, 2005, 141(2):199-206.
[9] Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer [J]. J Med Genet, 2006, 43(1):18-27.
pmid: 15937070
[10] Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment [J]. Fam Cancer, 2014, 13(4):637-644.
doi: 10.1007/s10689-014-9735-2 pmid: 25012257
[11] Ooi A. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research [J]. Semin Cancer Biol, 2020, 61:158-166.
doi: 10.1016/j.semcancer.2019.10.016
[12] Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency [J]. Hum Mol Genet, 2003, 12(11):1241-1252.
pmid: 12761039
[13] Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics [J]. Fam Cancer, 2011, 10(2):397-411.
doi: 10.1007/s10689-011-9428-z pmid: 21404119
[14] Lau HD, Chan E, Fan AC, et al. A clinicopathologic and mole-cular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients [J]. Am J Surg Pathol, 2020, 44(1):98-110.
doi: 10.1097/PAS.0000000000001372
[15] Muller M, Ferlicot S, Guillaud-Bataille M, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers [J]. Clin Genet, 2017, 92(6):606-615.
doi: 10.1111/cge.13014 pmid: 28300276
[16] Alderson NL, Wang Y, Blatnik M, et al. S-(2-succinyl)cys-teine: A novel chemical modification of tissue proteins by a Krebs cycle intermediate [J]. Arch Biochem Biophys, 2006, 450(1):1-8.
pmid: 16624247
[17] Gupta S, Swanson AA, Chen Y, et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC [J]. Hum Pathol, 2019, 91:114-122.
doi: 10.1016/j.humpath.2019.07.004
[18] Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome [J]. Am J Surg Pathol, 2016, 40(7):865-875.
doi: 10.1097/PAS.0000000000000617 pmid: 26900816
[19] Muller M, Guillaud-Bataille M, Salleron J, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration [J]. Mod Pathol, 2018, 31(6):974-983.
doi: 10.1038/s41379-018-0017-7
[20] Wong MH, Tan CS, Lee SC, et al. Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC) [J]. Fam Cancer, 2014, 13(2):281-289.
doi: 10.1007/s10689-014-9703-x pmid: 24526232
[21] Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fuma-rate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America [J]. Am J Hum Genet, 2003, 73(1):95-106.
doi: 10.1086/376435
[22] Hol JA, Jongmans MCJ, Littooij AS, et al. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature [J]. Fam Cancer, 2020, 19(1):55-63.
doi: 10.1007/s10689-019-00155-3 pmid: 31792767
[23] Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome [J]. Am J Surg Pathol, 2007, 31(10):1578-1585.
pmid: 17895761
[24] Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs: part A: renal, penile, and testicular tumours [J]. Eur Urol, 2016, 70(1):93-105.
doi: 10.1016/j.eururo.2016.02.029
[25] Ohe C, Smith SC, Sirohi D, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma [J]. Am J Surg Pathol, 2018, 42(3):279-292.
doi: 10.1097/PAS.0000000000001000
[26] Smith SC, Trpkov K, Chen YB, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: A frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma [J]. Am J Surg Pathol, 2016, 40(11):1457-1472.
doi: 10.1097/PAS.0000000000000719
[27] Forde C, Lim D, Alwan Y, et al. Hereditary leiomyomatosis and renal cell cancer: Clinical, molecular, and screening features in a cohort of 185 affected individuals [J]. Eur Urol Oncol, 2020, 3(6):764-772.
[28] Smith SC, Sirohi D, Ohe C, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morpholo-gically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma [J]. Histopathology, 2017, 71(1):42-52.
doi: 10.1111/his.2017.71.issue-1
[29] Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer [J]. Proc Natl Acad Sci USA, 2001, 98(6):3387-3392.
doi: 10.1073/pnas.051633798
[30] Choi Y, Keam B, Kim M, et al. Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients [J]. Cancer Res Treat, 2019, 51(4):1549-1556.
doi: 10.4143/crt.2019.086
[31] Verine J, Pluvinage A, Bousquet G, et al. Hereditary renal cancer syndromes: An update of a systematic review [J]. Eur Urol, 2010, 58(5):701-710.
doi: 10.1016/j.eururo.2010.08.031
[32] Joly D, Mejean A, Correas JM, et al. Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease [J]. J Urol, 2011, 185(6):2056-2060.
doi: 10.1016/j.juro.2011.02.007
[33] Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2. 2018, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(7):874-901.
doi: 10.6004/jnccn.2018.0061
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[3] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[4] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[5] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[6] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[7] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[8] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[9] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[10] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[11] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[12] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
[13] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[14] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[15] Yun-yi XU,Zheng-zheng SU,Lin-mao ZHENG,Meng-ni ZHANG,Jun-ya TAN,Ya-lan YANG,Meng-xin ZHANG,Miao XU,Ni CHEN,Xue-qin CHEN,Qiao ZHOU. Read-through circular RNA rt-circ-HS promotes hypoxia inducible factor 1α expression and renal carcinoma cell proliferation, migration and invasiveness [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 217-227.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd